| SKU | ISG004881 |
| Brand | ميتاكارديا |
| Categories | Medication & Treatments |
| Color | black |
| Shop by Concerns | Chest Discomfort |
| Gender | Neutral |
| Shop By Goals | Angina Control |
| Imported Or Local | Local |
| Ingredient | Trimetazidine |
| UPC | 6223002141128 |
| Product Form | Tablets |
| Specialty | Adjunct Therapy Cardioprotective Modified Release |
| Sub Categories | Anti Heamorrhagic |
| Unit Count | 30 Tablets |
| Warning | Caution in Renal Impairment May Cause Dizziness Not for acute conditions Use under medical supervision only |
Metacardia Mr 30 Tablets
Description:
Metacardia MR 35 mg 30 f.c. tablets is a prescription cardiovascular medicine containing trimetazidine, an anti-ischemic (anti-anginal) agent with cytoprotective properties. It is used as an adjunct therapy in the management of stable angina pectoris to improve myocardial (heart muscle) tolerance to ischemia and help reduce the frequency of anginal attacks. Metacardia MR works by optimizing cardiac energy metabolism at the cellular level rather than altering blood pressure or heart rate, making it a supportive option in chronic coronary artery disease under medical supervision.
Indications:
- Adjunctive treatment of stable angina pectoris in adult patients with coronary artery disease.
- Helps reduce the frequency and severity of anginal attacks (chest pain related to myocardial ischemia).
- Improves exercise tolerance and decreases episodes of exertional chest discomfort when used alongside standard anti-anginal therapies (such as beta-blockers, calcium channel blockers, or nitrates).
- Supportive therapy to improve myocardial cellular tolerance to ischemia and oxidative stress.
Active Ingredients / Key Components:
- Trimetazidine dihydrochloride – 35 mg per modified-release film-coated tablet (mr 35 mg).
- Other excipients (tablet core and coating) – exact composition and concentrations , please check the product leaflet or the manufacturer’s official website; please refer to the official package leaflet for full excipient list.
Dosage & Administration / How to Use:
- Usual adult dose (typical clinical practice): 35 mg trimetazidine (1 modified-release tablet) taken twice daily, preferably morning and evening, or as directed by the prescribing physician. Exact dosing must follow your doctor’s instructions.
- Swallow the tablet whole with a sufficient amount of water; do not crush, chew, or break the modified-release tablet to maintain controlled release of the active ingredient.
- Can be taken with meals to improve gastrointestinal tolerance, unless otherwise advised by your doctor.
- Metacardia MR is used as add-on therapy and is not intended for the initial treatment of unstable angina or acute myocardial infarction.
- Do not exceed the prescribed dose or change the dosing schedule without consulting your cardiologist or healthcare provider.
- If you miss a dose, take it as soon as you remember unless it is almost time for the next dose. Do not double the dose to make up for a missed tablet.
Clinical Benefits:
- Helps reduce the frequency of anginal attacks by improving the heart muscle’s tolerance to ischemia.
- Enhances exercise tolerance and physical performance in patients with stable angina when used with standard anti-anginal therapy.
- Supports cellular energy metabolism by shifting myocardial energy production from fatty acid oxidation to more efficient glucose oxidation.
- Limits intracellular acidosis and reduces sodium and calcium overload during ischemic episodes, helping protect cardiac cells.
- Provides cytoprotective and antioxidant effects, helping protect cell membranes from free radical-induced damage.
- Does not significantly affect blood pressure or heart rate, making it suitable as an adjunct therapy in many patients under medical supervision.
Warnings & Contraindications:
- Metacardia MR (trimetazidine) is indicated only as adjunctive therapy for stable angina and must not be used for the treatment of unstable angina or acute myocardial infarction.
- Contraindicated in patients with known hypersensitivity to trimetazidine or any of the excipients.
- Not recommended in patients with severe renal impairment; dose adjustment or avoidance may be required in moderate renal impairment and in elderly patients. Always follow your doctor’s advice.
- Use with caution in patients with movement disorders (e.g., Parkinson’s disease, tremor, gait instability, restless leg syndrome), as trimetazidine has been associated with or may worsen extrapyramidal symptoms.
- If you develop symptoms such as tremor, rigidity, unsteady gait, or other abnormal movements, inform your doctor immediately; treatment may need to be discontinued.
- Consult your doctor before use if you are pregnant, planning pregnancy, or breastfeeding; safety data in pregnancy and lactation are limited.
- Inform your healthcare provider about all other medications you are taking, including cardiac drugs, antihypertensives, antidiabetics, and over-the-counter products.
- Patients with severe hepatic disease, severe renal disease, or significant neurological disorders should use this medicine only under strict medical supervision, if at all.
- May cause dizziness or drowsiness in some patients; if affected, avoid driving or operating machinery until you know how the medicine affects you.
- Not intended to diagnose, treat, cure, or prevent any disease on its own; it is used as part of a comprehensive treatment plan for coronary artery disease.
- Keep out of reach of children.
Side Effects:
- Common side effects may include nausea, vomiting, abdominal pain, indigestion, diarrhea, headache, dizziness, or fatigue. These are usually mild and transient.
- Less common side effects can include rash, pruritus (itching), or other hypersensitivity reactions.
- Neurological or movement-related side effects (extrapyramidal symptoms) such as tremor, rigidity, unsteady gait, or restless leg syndrome have been reported; these typically resolve after discontinuation of treatment.
- Very rare but serious reactions such as angioedema or severe allergic reactions require immediate medical attention.
- If you experience severe dizziness, fainting, chest pain not relieved by your usual medication, new or worsening neurological symptoms, or any unusual or persistent adverse effect, stop taking the medicine and seek medical advice promptly.
Storage Instructions:
Store in a cool, dry place away from direct sunlight. Keep container tightly closed in its original blister pack or carton to protect from moisture. Keep out of reach of children. Do not use after the expiry date stated on the packaging.
Specifications:
- Product type: Prescription cardiovascular medicine (anti-ischemic, anti-anginal).
- Active ingredient strength: trimetazidine dihydrochloride 35 mg per modified-release film-coated tablet.
- Form: Modified-release film-coated tablet (mr tablet).
- Pack size: 30 tablets per pack.
- Intended users: Adult patients with stable angina pectoris, as prescribed by a healthcare professional.
Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.
